MAY 7-8, 2015 • BETHESDA NORTH MARRIOTT HOTEL & CONFERENCE CENTER
Sessions on cancer immunotherapeutics, RSV vaccines, HIV, TB, and malaria vaccines, and models for regional synergy in vaccine development all await you at the Atlantic Vaccines and Immunotherapeutics Summit on May 7-8 at the Bethesda North Marriott. Renowned speakers will be leading sessions highlighting local innovation that is having a global impact. We are excited to announce that Stanley Erck, President and CEO of Novavax, will be leading a session titled, “The Next Billion Dollar Vaccine.” Mr. Erck was named President and Chief Executive Officer of Novavax in April 2011. He became a Novavax Director in June 2009 and beginning in February 2010, served as its Executive Chairman of the Board. From 2000 to 2008, Mr. Erck was President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc., and the MdBio Foundation.